Information Provided By: 
Fly News Breaks for July 30, 2019
CRSP
Jul 30, 2019 | 08:39 EDT
Roth Capital analyst Tony Butler raised his price target for Crispr Therapeutics to $65 from $50 after the company reported ending Q2 with $427.9M in cash, which is expected to support operations through 2020, and announced that the first TDT patient treated with CTX001 remains transfusion-independent beyond four months and that the FIH trial of CTX110 in NHL was initiated. The analyst reiterates a Buy rating on the shares based on his continued positive outlook.
News For CRSP From the Last 2 Days
CRSP
Apr 18, 2024 | 14:06 EDT
